BiOmarkers tO perSonalise Treatment of depression (BOOST depression)

BiOmarkers tO perSonalise Treatment of depression (BOOST depression) - Biomarkers for treatment of depression

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57365

Enrollment

900

Registered

2024-08-08

Start date

2026-02-02

Completion date

Unknown

Last updated

2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

clinical depression/major depressive disorder Depression

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients: • Diagnosis of major depressive disorder (MDD) classified according to the DSM-5 with a moderate to severe depression as assessed by an HDRS-17 score of >=14 • 18-75 years of age • Willingness and ability to give written informed consent and willingness and ability to understand, to participate, and to comply with the study requirements • Starting treatment for the depressive episode with CBT, sertraline, rTMS, ECT, or intranasal esketamine Healthy controls: • 18-75 years of age • Willingness and ability to give written informed consent and willingness and ability to understand, to participate, and to comply with the study requirements

Exclusion criteria

Exclusion criteria: Patients: • Diagnosis of bipolar disorder or psychotic disorder assessed by the MINI-S. Other comorbid disorders will not be excluded to ensure representativeness of the sample. • For MRI: contraindication such as metal implants, claustrophobia, and pregnancy • Major head trauma or neurological disease, current or in history Healthy controls: • A current or past psychiatric diagnosis, assessed by the MINI-S • Major head trauma or neurological disease, current or in history • For MRI: contraindications such as metal implants, claustrophobia, and pregnancy

Design outcomes

Primary

Measure	Time frame
The main study parameter for our primary objective is the machine learning performance of classifying antidepressive treatment responders and non-responders across five different treatments with the use of various biomarkers.	—

Secondary

Measure	Time frame
Main study parameters for our secondary objective are differential changes in epigenetic and neuroimaging (MRI, EEG) markers after treatment between outcome/diagnostic groups.	—

Countries

Netherlands

Contacts

Public ContactL.A. Mortel

Amsterdam UMC

l.a.vandemortel@amsterdamumc.nl020-8913674

Outcome results